Pre-market hot trades in US stocks: Livewire pre-market down 8.52%; BioAge Labs pre-market up 8.41%Price Alert·10 hours agoLVWR-7.73%BIOA+17.48%
Roth MKM Reaffirms Their Buy Rating on BioAge Labs, Inc. (BIOA)Tip Ranks·Jul 31 at 01:55 PMBIOA+17.48%
BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program AssumptionsTip Ranks·Jul 31 at 01:36 PMBIOA+17.48%
Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside PotentialTip Ranks·Jul 31 at 01:36 PMBIOA+17.48%
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipelinebusinessinsider·Jul 31 at 01:16 PMBIOA+17.48%GLUE-6.27%
BioAge Labs shares are trading lower amid possible sympathy with Novo Nordisk after its ZEUS phase 3 trial did not translate into a MACE risk reduction.benzinga_article·Jul 31 at 11:20 AMBIOA+17.48%NVO+0.17%
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga_article·Jul 31 at 07:05 AMNUWE-5.34%REPL+11.21%
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk ReductionPR Newswire·Jul 14 at 03:30 AMBIOA+17.48%688222-4.24%
BioAge Labs principal accounting officer Shane Barton disposes of 62,566 common shares for $1,578,254.20PUBT·Jul 1 at 03:27 PMBIOA+17.48%
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye DiseaseMarket Beat·Jun 6 at 07:04 AMBIOA+17.48%
